Compound 1323
Identifiers
- Canonical SMILES:
CC[C@H](NC)C(=O)N[C@H]1CCC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1
- IUPAC name:
(3S,6S,9aS)-N-benzhydryl-6-[[(2S)-2-(methylamino)butanoyl]amino]-5-oxo-1,2,3,6,7,8,9,9a-octahydropyrrolo[1,2-a]azepine-3-carboxamide
- InChi:
InChI=1S/C28H36N4O3/c1-3-22(29-2)26(33)30-23-16-10-15-21-17-18-24(32(21)28(23)35)27(34)31-25(19-11-6-4-7-12-19)20-13-8-5-9-14-20/h4-9,11-14,21-25,29H,3,10,15-18H2,1-2H3,(H,30,33)(H,31,34)/t21-,22-,23-,24-/m0/s1
- InChiKey:
UKNQPDHAXSCGKL-ZJZGAYNASA-N
External links
![]() 11518553 |
![]() CHEMBL218832 |
![]() 9693341 |
BMB |
External search
|
|
|
|
|
Bibliography (3)
Pharmacological data
| Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
|---|---|---|---|
| 3 | 2 | 0 | 0 |
Targets
| PPI family | Best activity | Diseases | MMoA |
|---|---|---|---|
| XIAP / Smac | 7.21 | cancer | Inhibition |
Physicochemical filters
| Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
|---|---|---|---|---|
| Compliance | ||||
| MW | 476.28 g/mol | |||
| HBA | 7 | |||
| HBD | 3 | |||
| HBA + HBD | 10 | |||
| AlogP | 3.05 | |||
| TPSA | 90.54 | |||
| RB | 8 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
| Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
|---|---|---|---|---|
| 3 | 3 | 2 | 0 | 0 |
Pharmacological data
| Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
|---|---|---|---|---|---|---|---|---|
| 19620011 | 1b | XIAP P98170 |
|
Biochemical assay | Fluorescence Polarization | pIC50 (half maximal inhibitory concentration, -log10) | 6.28 | |
| 17181177 | 2 | XIAP P98170 |
|
Biochemical assay | Fluorescence Polarization | pKi (inhibition constant, -log10) | 7.21 | |
| 18954041 | 13 | XIAP P98170 |
|
Biochemical assay | Fluorescence Polarization | pKi (inhibition constant, -log10) | 7.21 | |
| 19620011 | 1b | XIAP P98170 |
|
Cellular assay | Proliferation assay | MDA-MB-231 | pIC50 (half maximal inhibitory concentration, -log10) | 6.84 |
| 17181177 | 2 | XIAP P98170 |
|
Cellular assay | Proliferation assay | MDA-MB-231 | pIC50 (half maximal inhibitory concentration, -log10) | 7.00 |
| Ta | Structure | Name | Drugbank ID |
|---|---|---|---|
| 0.7935 | 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide | DB07190 | |
| 0.7850 | D-phenylalanyl-N-benzyl-L-prolinamide | DB07143 | |
| 0.7802 | N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide | DB06858 | |
| 0.7717 | N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide | DB06853 | |
| 0.7717 | (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide | DB07095 | |
| 0.7717 | (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide | DB07131 | |
| 0.7609 | (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide | DB06850 | |
| 0.7582 | 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide | DB06878 | |
| 0.7582 | D-leucyl-N-(3-chlorobenzyl)-L-prolinamide | DB06911 | |
| 0.7582 | 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide | DB06947 | |
| 0.7582 | D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide | DB06996 | |
| 0.7526 | D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide | DB07133 | |
| 0.7400 | 1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide | DB02628 | |
| 0.7391 | (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide | DB06845 | |
| 0.7363 | N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide | DB06868 |




